Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2014

01.07.2014 | Review

Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis

verfasst von: Francisco E. Vera-Badillo, Marc Napoleone, Alberto Ocana, Arnoud J. Templeton, Bostjan Seruga, Mustafa Al-Mubarak, Hashem AlHashem, Ian F. Tannock, Eitan Amir

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Women with multifocal or multicentric breast tumors (multifocality henceforth) have been reported to have greater probability of nodal metastasis and relapse and worse survival than women with unifocal tumors. However, these associations have been inconsistent and multifocality is not taken into account by staging guidelines and prognostic models. A systematic review of electronic databases identified publications exploring the association between multifocality and overall survival (OS), disease-free survival (DFS), disease-specific survival (DSS), and loco-regional relapse (LRR). The hazard ratios (HRs) for OS and DFS for multifocal compared to unifocal tumors were extracted from multivariable analyses and included in a meta-analysis. For studies not reporting multivariable analyses, odds ratios (OR) were estimated from Kaplan–Meier curves for all endpoints at 5 and 10 years. Twenty-two studies comprising 67,557 women were included. Multifocality was reported in 9.5 % of patients. Classical prognostic factors were well balanced between unifocal and multifocal populations. In multivariable analyses, multifocality was associated with significantly worse OS (HR 1.65; P = 0.02), and a non-significant association with worse DFS (HR 1.96; P = 0.07). In univariable analyses, multifocality was associated with worse OS, DFS, DSS, and LRR at 5 years (OR 1.39, P = 0.02; OR 1.52, P = 0.02; OR 1.56, P = 0.03; and OR 3.23, P = 0.02, respectively). Similar estimates were observed at 10 years, but statistical significance was only reached for DSS and LRR. Mutifocality appears to be associated with a worse prognosis, however, substantial inter-study heterogeneity limits the precise determination of increased risk. Further validation of the independent prognostic impact of multifocality is warranted.
Literatur
2.
Zurück zum Zitat Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826PubMedCrossRef Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826PubMedCrossRef
3.
Zurück zum Zitat Van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536PubMedCrossRef Van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536PubMedCrossRef
4.
Zurück zum Zitat National Cancer Institute, NCI (2000) Genetic testing or clinical assessment in determining the need for chemotherapy in women with breast cancer that involves no more than 3 lymph nodes. In: ClinicalTrials.gov (internet). National Library of Medicine (US), Bethesda. Accessed 21 May 2014. http://clinicaltrials.gov/ct2/show/NCT00433589. NLM Identifier: NCT00433589 National Cancer Institute, NCI (2000) Genetic testing or clinical assessment in determining the need for chemotherapy in women with breast cancer that involves no more than 3 lymph nodes. In: ClinicalTrials.gov (internet). National Library of Medicine (US), Bethesda. Accessed 21 May 2014. http://​clinicaltrials.​gov/​ct2/​show/​NCT00433589. NLM Identifier: NCT00433589
5.
Zurück zum Zitat Ustaalioglu BO, Bilici A, Kefeli U, Seker M, Oncel M, Gezen C, Gumus M, Demirelli F (2012) The importance of multifocal/multicentric tumor on the disease-free survival of breast cancer patients: single center experience. Am J Clin Oncol 35(6):580–586PubMedCrossRef Ustaalioglu BO, Bilici A, Kefeli U, Seker M, Oncel M, Gezen C, Gumus M, Demirelli F (2012) The importance of multifocal/multicentric tumor on the disease-free survival of breast cancer patients: single center experience. Am J Clin Oncol 35(6):580–586PubMedCrossRef
6.
Zurück zum Zitat Fowble B, Yeh IT, Schultz DJ, Solin LJ, Rosato EF, Jardines L, Hoffman J, Eisenberg B, Weiss MC, Hanks G (1993) The role of mastectomy in patients with stage I–II breast cancer presenting with gross multifocal or multicentric disease or diffuse microcalcifications. Int J Radiat Oncol Biol Phys 27(3):567–573PubMedCrossRef Fowble B, Yeh IT, Schultz DJ, Solin LJ, Rosato EF, Jardines L, Hoffman J, Eisenberg B, Weiss MC, Hanks G (1993) The role of mastectomy in patients with stage I–II breast cancer presenting with gross multifocal or multicentric disease or diffuse microcalcifications. Int J Radiat Oncol Biol Phys 27(3):567–573PubMedCrossRef
7.
Zurück zum Zitat Eeles R, Knee G, Jhavar S, Mangion J, Ebbs S, Gui G, Thomas S, Coppen M, A’Hern R, Gray S et al (2011) Multicentric breast cancer: clonality and prognostic studies. Breast Cancer Res Treat 129(3):703–716PubMedCrossRef Eeles R, Knee G, Jhavar S, Mangion J, Ebbs S, Gui G, Thomas S, Coppen M, A’Hern R, Gray S et al (2011) Multicentric breast cancer: clonality and prognostic studies. Breast Cancer Res Treat 129(3):703–716PubMedCrossRef
8.
Zurück zum Zitat Yerushalmi R, Kennecke H, Woods R, Olivotto IA, Speers C, Gelmon KA (2009) Does multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence. Breast Cancer Res Treat 117(2):365–370PubMedCrossRef Yerushalmi R, Kennecke H, Woods R, Olivotto IA, Speers C, Gelmon KA (2009) Does multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence. Breast Cancer Res Treat 117(2):365–370PubMedCrossRef
9.
Zurück zum Zitat Fisher B, Slack NH, Bross ID (1969) Cancer of the breast: size of neoplasm and prognosis. Cancer 24(5):1071–1080PubMedCrossRef Fisher B, Slack NH, Bross ID (1969) Cancer of the breast: size of neoplasm and prognosis. Cancer 24(5):1071–1080PubMedCrossRef
10.
Zurück zum Zitat Edge SB, Byrd DR, Fritzz AG et al (2010) AJCC cancer staging manual, 7th edn. Springer, New York Edge SB, Byrd DR, Fritzz AG et al (2010) AJCC cancer staging manual, 7th edn. Springer, New York
11.
Zurück zum Zitat Coombs NJ, Boyages J (2005) Multifocal and multicentric breast cancer: does each focus matter? [Erratum appears in J Clin Oncol. 2006 Apr 1;24(10):1648]. J Clin Oncol 23(30):7497–7502PubMedCrossRef Coombs NJ, Boyages J (2005) Multifocal and multicentric breast cancer: does each focus matter? [Erratum appears in J Clin Oncol. 2006 Apr 1;24(10):1648]. J Clin Oncol 23(30):7497–7502PubMedCrossRef
12.
Zurück zum Zitat Boyages J, Jayasinghe UW, Coombs N (2010) Multifocal breast cancer and survival: each focus does matter particularly for larger tumours. Eur J Cancer 46(11):1990–1996PubMedCrossRef Boyages J, Jayasinghe UW, Coombs N (2010) Multifocal breast cancer and survival: each focus does matter particularly for larger tumours. Eur J Cancer 46(11):1990–1996PubMedCrossRef
13.
Zurück zum Zitat Cabioglu N, Ozmen V, Kaya H, Tuzlali S, Igci A, Muslumanoglu M, Kecer M, Dagoglu T (2009) Increased lymph node positivity in multifocal and multicentric breast cancer. J Am Coll Surg 208(1):67–74PubMedCrossRef Cabioglu N, Ozmen V, Kaya H, Tuzlali S, Igci A, Muslumanoglu M, Kecer M, Dagoglu T (2009) Increased lymph node positivity in multifocal and multicentric breast cancer. J Am Coll Surg 208(1):67–74PubMedCrossRef
14.
Zurück zum Zitat Joergensen LE, Gunnarsdottir KA, Lanng C, Moeller S, Rasmussen BB (2008) Multifocality as a prognostic factor in breast cancer patients registered in Danish Breast Cancer Cooperative Group (DBCG) 1996–2001. Breast 17(6):587–591PubMedCrossRef Joergensen LE, Gunnarsdottir KA, Lanng C, Moeller S, Rasmussen BB (2008) Multifocality as a prognostic factor in breast cancer patients registered in Danish Breast Cancer Cooperative Group (DBCG) 1996–2001. Breast 17(6):587–591PubMedCrossRef
15.
Zurück zum Zitat Pedersen L, Gunnarsdottir KA, Rasmussen BB, Moeller S, Lanng C (2004) The prognostic influence of multifocality in breast cancer patients. Breast 13(3):188–193PubMedCrossRef Pedersen L, Gunnarsdottir KA, Rasmussen BB, Moeller S, Lanng C (2004) The prognostic influence of multifocality in breast cancer patients. Breast 13(3):188–193PubMedCrossRef
16.
Zurück zum Zitat Chung AP, Huynh K, Kidner T, Mirzadehgan P, Sim M-S, Giuliano AE (2012) Comparison of outcomes of breast conserving therapy in multifocal and unifocal invasive breast cancer. J Am Coll Surg 215(1):137–146 discussion 146–147PubMedCrossRef Chung AP, Huynh K, Kidner T, Mirzadehgan P, Sim M-S, Giuliano AE (2012) Comparison of outcomes of breast conserving therapy in multifocal and unifocal invasive breast cancer. J Am Coll Surg 215(1):137–146 discussion 146–147PubMedCrossRef
17.
Zurück zum Zitat Bendifallah S, Werkoff G, Borie-Moutafoff C, Antoine M, Chopier J, Gligorov J, Uzan S, Coutant C, Rouzier R (2010) Multiple synchronous (multifocal and multicentric) breast cancer: clinical implications. Surg Oncol 19(4):e115–e123PubMedCrossRef Bendifallah S, Werkoff G, Borie-Moutafoff C, Antoine M, Chopier J, Gligorov J, Uzan S, Coutant C, Rouzier R (2010) Multiple synchronous (multifocal and multicentric) breast cancer: clinical implications. Surg Oncol 19(4):e115–e123PubMedCrossRef
18.
Zurück zum Zitat Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6(7):e1000100PubMedCentralPubMedCrossRef Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6(7):e1000100PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Michiels S, Piedbois P, Burdett S, Syz N, Stewart L, Pignon JP (2005) Meta-analysis when only the median survival times are known: a comparison with individual patient data results. Int J Technol Assess Health Care 21(1):119–125PubMedCrossRef Michiels S, Piedbois P, Burdett S, Syz N, Stewart L, Pignon JP (2005) Meta-analysis when only the median survival times are known: a comparison with individual patient data results. Int J Technol Assess Health Care 21(1):119–125PubMedCrossRef
20.
21.
Zurück zum Zitat Oh JL, Dryden MJ, Woodward WA, Yu T-K, Tereffe W, Strom EA, Perkins GH, Middleton L, Hunt KK, Giordano SH et al (2006) Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy. J Clin Oncol 24(31):4971–4975PubMedCrossRef Oh JL, Dryden MJ, Woodward WA, Yu T-K, Tereffe W, Strom EA, Perkins GH, Middleton L, Hunt KK, Giordano SH et al (2006) Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy. J Clin Oncol 24(31):4971–4975PubMedCrossRef
22.
Zurück zum Zitat Okumura S, Mitsumori M, Yamauchi C, Kawamura S, Oya N, Nagata Y, Hiraoka M, Kokubo M, Mise K, Kodama H (2004) Feasibility of breast-conserving therapy for macroscopically multiple ipsilateral breast cancer. Int J Radiat Oncol Biol Phys 59(1):146–151PubMedCrossRef Okumura S, Mitsumori M, Yamauchi C, Kawamura S, Oya N, Nagata Y, Hiraoka M, Kokubo M, Mise K, Kodama H (2004) Feasibility of breast-conserving therapy for macroscopically multiple ipsilateral breast cancer. Int J Radiat Oncol Biol Phys 59(1):146–151PubMedCrossRef
23.
Zurück zum Zitat Litton JK, Eralp Y, Gonzalez-Angulo AM, Broglio K, Uyei A, Hortobagyi GN, Arun B (2007) Multifocal breast cancer in women ≤35 years old. Cancer 110(7):1445–1450PubMedCrossRef Litton JK, Eralp Y, Gonzalez-Angulo AM, Broglio K, Uyei A, Hortobagyi GN, Arun B (2007) Multifocal breast cancer in women ≤35 years old. Cancer 110(7):1445–1450PubMedCrossRef
24.
Zurück zum Zitat Lynch SP, Lei X, Chavez-MacGregor M, Hsu L, Meric-Bernstam F, Buchholz TA, Zhang A, Hortobagyi GN, Valero V, Gonzalez-Angulo AM (2012) Multifocality and multicentricity in breast cancer and survival outcomes. Ann Oncol 23(12):3063–3069PubMedCentralPubMedCrossRef Lynch SP, Lei X, Chavez-MacGregor M, Hsu L, Meric-Bernstam F, Buchholz TA, Zhang A, Hortobagyi GN, Valero V, Gonzalez-Angulo AM (2012) Multifocality and multicentricity in breast cancer and survival outcomes. Ann Oncol 23(12):3063–3069PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Tiong LU, Parkyn R, Walters D, Field J, Lai C, Walsh DCA (2011) Dilemma in multifocal breast cancer—largest versus aggregate diameter. ANZ J Surg 81(9):614–618PubMedCrossRef Tiong LU, Parkyn R, Walters D, Field J, Lai C, Walsh DCA (2011) Dilemma in multifocal breast cancer—largest versus aggregate diameter. ANZ J Surg 81(9):614–618PubMedCrossRef
26.
Zurück zum Zitat Wilson LD, Beinfield M, McKhann CF, Haffty BG (1993) Conservative surgery and radiation in the treatment of synchronous ipsilateral breast cancers. Cancer 72(1):137–142PubMedCrossRef Wilson LD, Beinfield M, McKhann CF, Haffty BG (1993) Conservative surgery and radiation in the treatment of synchronous ipsilateral breast cancers. Cancer 72(1):137–142PubMedCrossRef
27.
Zurück zum Zitat Egan RL (1982) Multicentric breast carcinomas: clinical–radiographic–pathologic whole organ studies and 10-year survival. Cancer 49(6):1123–1130PubMedCrossRef Egan RL (1982) Multicentric breast carcinomas: clinical–radiographic–pathologic whole organ studies and 10-year survival. Cancer 49(6):1123–1130PubMedCrossRef
28.
Zurück zum Zitat Middleton LP, Vlastos G, Mirza NQ, Eva S, Sahin AA (2002) Multicentric mammary carcinoma: evidence of monoclonal proliferation. Cancer 94(7):1910–1916PubMedCrossRef Middleton LP, Vlastos G, Mirza NQ, Eva S, Sahin AA (2002) Multicentric mammary carcinoma: evidence of monoclonal proliferation. Cancer 94(7):1910–1916PubMedCrossRef
29.
Zurück zum Zitat Vlastos G, Rubio IT, Mirza NQ, Newman LA, Aurora R, Alderfer J, Buzdar AU, Singletary SE (2000) Impact of multicentricity on clinical outcome in patients with T1-2, N0-1, M0 breast cancer. Ann Surg Oncol 7(8):581–587PubMedCrossRef Vlastos G, Rubio IT, Mirza NQ, Newman LA, Aurora R, Alderfer J, Buzdar AU, Singletary SE (2000) Impact of multicentricity on clinical outcome in patients with T1-2, N0-1, M0 breast cancer. Ann Surg Oncol 7(8):581–587PubMedCrossRef
30.
Zurück zum Zitat Weissenbacher TM, Zschage M, Janni W, Jeschke U, Dimpfl T, Mayr D, Rack B, Schindlbeck C, Friese K, Dian D (2010) Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified? Breast Cancer Res Treat 122(1):27–34PubMedCrossRef Weissenbacher TM, Zschage M, Janni W, Jeschke U, Dimpfl T, Mayr D, Rack B, Schindlbeck C, Friese K, Dian D (2010) Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified? Breast Cancer Res Treat 122(1):27–34PubMedCrossRef
31.
Zurück zum Zitat Pekar G, Hofmeyer S, Tabar L, Tarjan M, Chen TH-H, Yen AM-F, Chiu SY-H, Hellberg D, Gere M, Tot T (2013) Multifocal breast cancer documented in large-format histology sections: long-term follow-up results by molecular phenotypes. Cancer 119(6):1132–1139PubMedCrossRef Pekar G, Hofmeyer S, Tabar L, Tarjan M, Chen TH-H, Yen AM-F, Chiu SY-H, Hellberg D, Gere M, Tot T (2013) Multifocal breast cancer documented in large-format histology sections: long-term follow-up results by molecular phenotypes. Cancer 119(6):1132–1139PubMedCrossRef
32.
Zurück zum Zitat Tot T, Gere M, Pekar G, Tarjan M, Hofmeyer S, Hellberg D, Lindquist D, Chen TH-H, Yen AM-F, Chiu SY-H et al (2011) Breast cancer multifocality, disease extent, and survival. Hum Pathol 42(11):1761–1769PubMedCrossRef Tot T, Gere M, Pekar G, Tarjan M, Hofmeyer S, Hellberg D, Lindquist D, Chen TH-H, Yen AM-F, Chiu SY-H et al (2011) Breast cancer multifocality, disease extent, and survival. Hum Pathol 42(11):1761–1769PubMedCrossRef
33.
Zurück zum Zitat Katz A, Strom EA, Buchholz TA, Theriault R, Singletary SE, McNeese MD (2001) The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy. Int J Radiat Oncol Biol Phys 50(3):735–742PubMedCrossRef Katz A, Strom EA, Buchholz TA, Theriault R, Singletary SE, McNeese MD (2001) The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy. Int J Radiat Oncol Biol Phys 50(3):735–742PubMedCrossRef
34.
Zurück zum Zitat Kurtz JM, Jacquemier J, Amalric R, Brandone H, Ayme Y, Hans D, Bressac C, Spitalier JM (1990) Breast-conserving therapy for macroscopically multiple cancers. Ann Surg 212(1):38–44PubMedCentralPubMedCrossRef Kurtz JM, Jacquemier J, Amalric R, Brandone H, Ayme Y, Hans D, Bressac C, Spitalier JM (1990) Breast-conserving therapy for macroscopically multiple cancers. Ann Surg 212(1):38–44PubMedCentralPubMedCrossRef
35.
Zurück zum Zitat Black WC, Haggstrom DA, Welch HG (2002) All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst 94(3):167–173PubMedCrossRef Black WC, Haggstrom DA, Welch HG (2002) All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst 94(3):167–173PubMedCrossRef
36.
Zurück zum Zitat Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503):2087–2106PubMedCrossRef Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503):2087–2106PubMedCrossRef
37.
Zurück zum Zitat Nakamura R, Song JP, Isogaki J, Kitayama Y, Sugimura H (2003) Multiple (multicentric and multifocal) cancers in the ipsilateral breast with different histologies: profiles of chromosomal numerical abnormality. Jpn J Clin Oncol 33(9):463–469PubMedCrossRef Nakamura R, Song JP, Isogaki J, Kitayama Y, Sugimura H (2003) Multiple (multicentric and multifocal) cancers in the ipsilateral breast with different histologies: profiles of chromosomal numerical abnormality. Jpn J Clin Oncol 33(9):463–469PubMedCrossRef
38.
Zurück zum Zitat Buggi F, Folli S, Curcio A, Casadei-Giunchi D, Rocca A, Pietri E, Medri L, Serra L (2012) Multicentric/multifocal breast cancer with a single histotype: is the biological characterization of all individual foci justified? Ann Oncol 23(8):2042–2046PubMedCrossRef Buggi F, Folli S, Curcio A, Casadei-Giunchi D, Rocca A, Pietri E, Medri L, Serra L (2012) Multicentric/multifocal breast cancer with a single histotype: is the biological characterization of all individual foci justified? Ann Oncol 23(8):2042–2046PubMedCrossRef
39.
Zurück zum Zitat Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, Hayes DF, Kleer C, O’Malley FP, Page DL et al (2009) Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med 133(10):1515–1538PubMed Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, Hayes DF, Kleer C, O’Malley FP, Page DL et al (2009) Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med 133(10):1515–1538PubMed
40.
Zurück zum Zitat Yerushalmi R, Tyldesley S, Woods R, Kennecke HF, Speers C, Gelmon KA (2012) Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality? Ann Oncol 23(4):876–881PubMedCrossRef Yerushalmi R, Tyldesley S, Woods R, Kennecke HF, Speers C, Gelmon KA (2012) Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality? Ann Oncol 23(4):876–881PubMedCrossRef
Metadaten
Titel
Effect of multifocality and multicentricity on outcome in early stage breast cancer: a systematic review and meta-analysis
verfasst von
Francisco E. Vera-Badillo
Marc Napoleone
Alberto Ocana
Arnoud J. Templeton
Bostjan Seruga
Mustafa Al-Mubarak
Hashem AlHashem
Ian F. Tannock
Eitan Amir
Publikationsdatum
01.07.2014
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2014
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-014-3018-3

Weitere Artikel der Ausgabe 2/2014

Breast Cancer Research and Treatment 2/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.